
Immune-checkpoint inhibitors (ICIs) have substantially improved the outcomes of large subsets of patients across numerous malignancies. However, the lack of durable responses in many patients, added to high costs and the risk of adverse events, indicates a need for better biomarkers to guide patient selection.
Like
Save
Share